Synteract is an innovative CRO providing full-service, Phase I-IV services to biopharma companies in bringing new medicines to market. We align our operational excellence, therapeutic expertise and the right technology to support each client’s clinical development needs. Over its nearly 30-year history, Synteract’s leadership has been proven in the core development areas of oncology, neuro-degenerative disorders, rare/orphan disease, pediatrics, and dermatology, and has contributed to more than 240 product approvals in these and additional therapeutic areas.